H3 G34 mutation assessment for diffuse gliomas in adults: when would testing be most diagnostically useful?
J Neuropathol Exp Neurol
.
2022 Dec 19;82(1):93-95.
doi: 10.1093/jnen/nlac102.
Authors
Jorge A Trejo-Lopez
1
,
Corinne E Praska
1
,
Cinthya Zepeda Mendoza
1
,
Thomas M Kollmeyer
1
,
Aditya Raghunathan
1
,
Caterina Giannini
1
,
Rachael A Vaubel
1
,
Aivi Nguyen
1
,
Mark E Jentoft
2
,
Kliment Donev
3
,
Gang Zheng
1
,
Margaret A DiGuardo
1
,
Benjamin R Kipp
1
,
Robert B Jenkins
1
,
Cristiane M Ida
1
Affiliations
1
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
2
Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
3
Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona, USA.
PMID:
36326576
DOI:
10.1093/jnen/nlac102
No abstract available
Publication types
Letter
MeSH terms
Adult
Brain Neoplasms* / genetics
Glioma* / genetics
Humans
Mutation